These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2124634)

  • 21. [Effects of isepamicin and beta-lactam antibiotics on the release of endotoxin from Pseudomonas aeruginosa].
    Yamaguchi S; Sato S; Toriya M; Tsuji A
    Jpn J Antibiot; 1999 Jan; 52(1):41-56. PubMed ID: 10202687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Susceptibility of clinical isolates to aztreonam].
    Asari S; Horikawa M; Tsukamoto H; Kouda K; Hayashi C; Miyai K
    Jpn J Antibiot; 1987 Jul; 40(7):1317-31. PubMed ID: 3479624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].
    Bartmann K; Tarbuc R
    Infection; 1982; 10(6):361-70. PubMed ID: 6818153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus].
    Maekawa M; Takahashi K; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):440-5. PubMed ID: 12378872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Latamoxef in combination with aminoglycosides against Pseudomonas aeruginosa: similarity with ticarcillin.
    Sears SD; Tatem BA; Standiford HC
    Chemotherapy; 1985; 31(2):102-11. PubMed ID: 3921317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
    Daimon Y
    Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antibacterial activities of combination uses of cefpirome with various antibiotics in vitro against clinically isolated glucose non-fermentative gram-negative rods: part 1. the results against Pseudomonas aeruginosa].
    Suzuki Y; Koguchi M; Fukayama S; Ishihara R; Oda S; Deguchi K
    Jpn J Antibiot; 1996 Jan; 49(1):71-82. PubMed ID: 8851306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.
    Shaaban MI; Shaker MA; Mady FM
    J Nanobiotechnology; 2017 Apr; 15(1):29. PubMed ID: 28399890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Basic studies on combination effects of arbekacin and beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus].
    Watanabe T; Sobu K; Takase Y; Kawabata T; Kanno M; Yoshida T
    Jpn J Antibiot; 1994 Jun; 47(6):701-9. PubMed ID: 8072178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.
    Weinstein RJ; Young LS; Hewitt WL
    J Lab Clin Med; 1975 Nov; 86(5):853-62. PubMed ID: 810533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.
    Wang FD; Lin ML; Lee WS; Liu CY
    Int J Antimicrob Agents; 2004 Jun; 23(6):590-5. PubMed ID: 15194130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
    Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
    Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro effects of combinations of antibiotics against highly-fosfomycin-resistant, methicillin-resistant Staphylococcus aureus. With special reference to efficacies of combinations of imipenem/cilastatin and cephems].
    Kouda M
    Jpn J Antibiot; 1993 Feb; 46(2):142-53. PubMed ID: 8331774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1987). I. Susceptibility distribution].
    Kosakai N; Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1990 Jun; 43(6):919-53. PubMed ID: 2122040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro synergistic effects of tazobactam/piperacillin with various antibiotics].
    Nishida K; Niidome K; Hashimoto M; Otsuki M; Nishino T
    Jpn J Antibiot; 1994 Oct; 47(10):1348-62. PubMed ID: 7807695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa.
    Van Laethem Y; Husson M; Klastersky J
    Antimicrob Agents Chemother; 1984 Aug; 26(2):224-7. PubMed ID: 6435515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders].
    Sawae Y; Niho Y; Okamura T; Gondo H; Kozuru M; Uike N; Muta K; Goto T; Suehiro Y; Kumakawa M; Nishimura J; Yufu Y; Ishikura H; Yamashita S; Hisano S; Morioka E; Nakajima H; Shibuya T; Yamasaki K; Harada N; Asayama R; Hayashi S; Akashi K; Suematsu E; Kawasaki C
    Jpn J Antibiot; 1996 Dec; 49(12):1049-61. PubMed ID: 9032592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.